While Some Pharma Firms Contemplate A Move From Europe, Lilly Plants More R&D Roots
This article was originally published in The Pink Sheet Daily
Pricing and reimbursement concerns in Europe could have a knock-on effect on R&D there, but with new academic tie-ups, Lilly says this is the time to invest.
You may also be interested in...
GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products
The acquisitions of two drug candidates - one from Lilly, one from a university - are the first in the pharma's latest scheme to share risk with VCs.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.